MEA Parenteral Nutrition Market Analysis By Type of Nutrition (Carbohydrates, Parenteral Lipid Emulsions, Single Dose Amino Acid Solution, Trace Elements, Vitamins & Minerals), By Dosage Form, By Region, And Segment Forecasts, 2014 - 2025

The MEA parenteral nutrition market is expected to reach USD 377.1 million by 2025 according to a new report by Grand View Research, Inc. The MEA parenteral nutrition market is expected to witness lucrative growth over the forecast period owing to various parameters such as presence of large pool of malnourished children, rising premature births, increasing adoption by healthcare settings for nutrient administration in chronically ill geriatric patients, and rising prevalence rate of cancer within the region.
Increasing prevalence of chronic conditions such as cancer unswervingly influences the use of parenteral nutrition across the globe. Parenteral nutrition helps in the administration of key vital nutrients that are useful in maintaining strength, energy, and hydration level in cancer patients, thus, acting a vital impact rendering driver expected to surge market growth over the forecast period.
Similarly, predominant existence of malnourished children and premature neonates that require these nutrients, is expected to further propel the growth. According to statistics published by the Knoema, a public data platform, the prevalence of the malnutrition in Middle East and North Africa in 2013 was around 6.04%, however, it has witnessed a decline over the period of time.
Further Key Findings From the Study Suggest:
‧ Single dose amino acid solutions held a dominant share in 2016. This dominance is governed by the influx of innovative products. In addition, these innovative formulations are more efficient and cause lesser adverse effects.
‧ Intravenous lipid emulsions are anticipated to witness lucrative growth over the forecast period. Drug delivery through lipid emulsion is expected to showcase promising results as it results in minimal adverse effects such as irritation, pain, and thrombophlebitis.
‧ Bags dominated the Middle East parenteral nutrition market with more than 67.00% share in 2016. These packaging materials are easy to handle, transport, and are cost-efficient.
‧ Vials are used for smaller concentration dose, often in hospital compounding. Increasing focus on customized treatment is likely to boost the usage of vials.
‧ Saudi Arabia held largest share in MEA parenteral nutrition market in 2016. However, countries such as Kuwait, Oman, Lebanon, and Jordan are anticipated to gain remunerative share over the forecast period.
‧ Key market players of the MEA parenteral nutrition industry are B. Braun Melsungen AG; Baxter; Fresenius Kabi AG; Hospira Inc.; Qatar Pharma Factory; Pharmaceutical Solutions Industry; Kuwait Saudi Pharmaceutical Industries Co.; Alfa Laboratories; and Well Pharma.

Table of Contents
Chapter 1. Methodology and Scope
1.1. Information Procurement
1.1.1. Purchased Database
1.1.2. GVR’s Internal Database
1.2. Data Analysis
1.3. Market Formulation & Validation
1.4. Approaches for Market Estimation
1.4.1. Approach 1: Commodity Flow & Bottom Up Approach
1.4.2. Approach 2: Top Down and Parent Market Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
Chapter 3. MEA Parenteral Nutrition Market Variables, Trends & Scope
3.1. Market Segmentation & Scope
3.2. Market Driver Analysis
3.2.1. Increasing natality rate
3.2.2. Risk of malnutrition
3.3. Market Restraint Analysis
3.3.1. Increased use of enteral nutrition
3.3.2. High risk of infection
3.4. Penetration & Growth Prospect Mapping
3.5. SWOT Analysis, by Factor
3.5.1. Political
3.5.2. Economic
3.5.3. Technological
3.6. Industry Analysis - Porter’s
Chapter 4. MEA Parenteral Nutrition: Nutrient Type Estimates & Trend Analysis
4.1. MEA Parenteral Nutrition Market Share, 2016 & 2025
4.2. Market Size, Estimates & Forecasts and Trend Analyses, 2014 to 2025 for the following nutrient types:
4.2.1. Carbohydrates
4.2.1.1. Carbohydrates market estimates and forecasts, 2014 to 2025
4.2.2. Parenteral Lipid Emulsions
4.2.2.1. Parenteral lipid emulsions market estimates and forecasts, 2014 to 2025
4.2.3. Single Dose Amino Acid Solutions
4.2.3.1. Single dose amino acid solutions market estimates and forecasts, 2014 to 2025
4.2.4. Trace Elements
4.2.4.1. Trace elements market estimates and forecasts, 2014 to 2025
4.2.5. Vitamins and Minerals
4.2.5.1. Vitamins and minerals market estimates and forecasts, 2014 to 2025
Chapter 5. MEA Parenteral Nutrition: Dosage Form Estimates & Trend Analysis
5.1. MEA Parenteral Nutrition Market Share, 2016 & 2025
5.2. Market Size, Estimates & Forecasts and Trend Analyses, 2014 to 2025 for the following applications:
5.2.1. Vials
5.2.1.1. Vials market estimates and forecasts, 2014 to 2025
5.2.2. Ampoules
5.2.2.1. Ampoules market estimates and forecasts, 2014 to 2025
5.2.3. Bottles
5.2.3.1. Bottles market estimates and forecasts, 2014 to 2025
5.2.4. Bags
5.2.4.1. Bags market estimates and forecasts, 2014 to 2025
5.2.4.2. Multi chambered bags
5.2.4.2.1. Multi chambered bags market estimates and forecasts, 2014 to 2025
5.2.4.3. Other bags
5.2.4.3.1. Other bags market estimates and forecasts, 2014 to 2025
Chapter 6. MEA Parenteral Nutrition: Regional Estimates & Trend Analysis
6.1. MEA Parenteral Nutrition Regional Movement Analysis & Market Share, 2016 & 2025
6.2. Saudi Arabia
6.2.1. Saudi Arabia revenue estimates and forecasts by, product, 2014 - 2025 (USD Million)
6.3. Qatar
6.3.1. Qatar revenue estimates and forecasts by, product, 2014 - 2025 (USD Million)
6.4. Kuwait
6.4.1. Kuwait revenue estimates and forecasts by, product, 2014 - 2025 (USD Million)
6.5. UAE
6.5.1. UAE revenue estimates and forecasts by, product, 2014 - 2025 (USD Million)
6.6. Saudi Arabia
6.6.1. Saudi Arabia revenue estimates and forecasts by, product, 2014 - 2025 (USD Million)
6.7. Oman
6.7.1. Oman revenue estimates and forecasts by, product, 2014 - 2025 (USD Million)
6.8. Egypt
6.8.1. Egypt revenue estimates and forecasts by, product, 2014 - 2025 (USD Million)
6.9. Lebanon
6.9.1. Lebanon revenue estimates and forecasts by, product, 2014 - 2025 (USD Million)
6.10. Jordan
6.10.1. Jordan revenue estimates and forecasts by, product, 2014 - 2025 (USD Million)
Chapter 7. Competitive Landscape
7.1. Strategy Framework
7.2. Company Profiles
7.2.1. B. Braun Melsungen AG
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Baxter
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Fresenius Kabi AG
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Pfizer, Inc.(Hospira)
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Otsuka Pharmaceutical Factory, Inc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Qatar Pharma Factory
7.2.6.1. Company overview
7.2.6.2. Product benchmarking
7.2.7. Pharmaceutical Solutions Industry
7.2.7.1. Company overview
7.2.7.2. Product benchmarking
7.2.8. Kuwait Saudi Pharmaceutical Industries Co.
7.2.8.1. Company overview
7.2.8.2. Product benchmarking
7.2.9. Alfa Laboratories
7.2.9.1. Company overview
7.2.9.2. Product benchmarking
7.2.9.3. Strategic initiatives
7.2.10. Well Pharma
7.2.10.1. Company overview
7.2.10.2. Product benchmarking
7.2.11. SP S.A.R.L (Serum Product Group)
7.2.11.1. Company overview
7.2.11.2. Product benchmarking